ALBERTA PRECISION LABORATORIES
Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	9 November 2026
TO:	All Zones – All Healthcare Providers
FROM:	Clinical Biochemistry, Alberta Precision Laboratories
RE:	**Update: Temporary Changes to Anti-Cardiolipin IgG Antibody Testing and Reporting**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- **Effective immediately**, the manufacturer reagent issues affecting anti-cardiolipin IgG antibody testing have been resolved. Testing and reporting are now resumed at APL.

Update

- Between May 4 to Nov 5, 2026, the University of Alberta Hospital (UAH) in Edmonton and the Diagnostic Scientific Centre (DSC) in Calgary were unable to report Anti-Cardiolipin IgG Antibody results ≥1.6 due to manufacturer reagent issues.
- New manufacturer reagent has been received and passed internal verification and quality review.
- Testing and reporting for Anti-Cardiolipin IgG is resumed.

Action Required

- Continue routine ordering practice
- No changes to test ordering, collection, or result reporting.

Questions/Concerns

- Dr. Kareena Schnabl, Clinical Biochemist, Edmonton, 780-407-3186, Kareena.Schnabl@aplabs.ca
- Dr. Qian Wang, Clinical Biochemist, Calgary, 403-770-3219, Qian.Wang@aplabs.ca

Approved by

- Dr. Allison Venner, Section Chief, Clinical Biochemistry, South Sector, APL
- Dr. Carolyn O'Hara, Interim Chief Medical Laboratory Officer, APL